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Summary
Background Disability in elderly people in countries with low and middle incomes is little studied; according to Global 
Burden of Disease estimates, visual impairment is the leading contributor to years lived with disability in this population. 
We aimed to assess the contribution of physical, mental, and cognitive chronic diseases to disability, and the extent to 
which sociodemographic and health characteristics account for geographical variation in disability. 
Methods We undertook cross-sectional surveys of residents aged older than 65 years (n=15 022) in 11 sites in 
seven countries with low and middle incomes (China, India, Cuba, Dominican Republic, Venezuela, Mexico, and 
Peru). Disability was assessed with the 12-item WHO disability assessment schedule 2.0. Dementia, depression, 
hypertension, and chronic obstructive pulmonary disease were ascertained by clinical assessment; diabetes, stroke, 
and heart disease by self-reported diagnosis; and sensory, gastrointestinal, skin, limb, and arthritic disorders by self-
reported impairment. Independent contributions to disability scores were assessed by zero-inﬂ ated negative binomial 
regression and Poisson regression to generate population-attributable prevalence fractions (PAPF).
Findings In regions other than rural India and Venezuela, dementia made the largest contribution to disability 
(median PAPF 25·1% [IQR 19·2–43·6]). Other substantial contributors were stroke (11·4% [1·8–21·4]), limb 
impairment (10·5% [5·7–33·8]), arthritis (9·9% [3·2–34·8]), depression (8·3% [0·5–23·0]), eyesight problems (6·8% 
[1·7–17·6]), and gastrointestinal impairments (6·5% [0·3–23·1]). Associations with chronic diseases accounted for 
around two-thirds of prevalent disability. When zero inﬂ ation was taken into account, between-site diﬀ erences in 
disability scores were largely attributable to compositional diﬀ erences in health and sociodemographic 
characteristics.
Interpretation On the basis of empirical research, dementia, not blindness, is overwhelmingly the most important 
independent contributor to disability for elderly people in countries with low and middle incomes. Chronic diseases 
of the brain and mind deserve increased prioritisation. Besides disability, they lead to dependency and present 
stressful, complex, long-term challenges to carers. Societal costs are enormous.
Funding Wellcome Trust; WHO; US Alzheimer’s Association; Fondo Nacional de Ciencia Y Tecnologia, Consejo de 
Desarrollo Cientiﬁ co Y Humanistico, Universidad Central de Venezuela.
Introduction
WHO’s International Classiﬁ cation of Functioning, 
Disability and Health1 deﬁ nes disability as “the negative 
aspects of the interaction between an individual (with a 
health condition) and that individual’s contextual factors 
(personal and environmental factors)”. Interactions are 
speciﬁ ed as including impairments (aﬀ ecting the body), 
activity limitations (aﬀ ecting actions or behaviour), and 
participation restrictions (aﬀ ecting experience of life). 
According to the Global Burden of Disease2 estimates for 
2004, 68% of the 751 million years lived with disability 
(YLD) worldwide are attributable to chronic non-
communicable diseases, and 84% of this burden of 
chronic-disease disability arises in countries with low 
and middle incomes. 
Although the prevalence and incidence of most 
chronic diseases are strongly age dependent, only 23% 
of the disabi lity burden caused by chronic disease in 
countries with low and middle incomes occurs in people 
aged 60 years and older, compared with 36% for high-
income countries, where demographic ageing is much 
more advanced. However, chronic-disease disability in 
elderly people in countries with low and middle incomes 
is set to increase sharply. Between 2010 and 2050, the 
number of people aged 60 years and older will increase 
by 56% in most developed regions (from 269 million to 
416 million, or from 21·8% to 32·6% of the total 
population), but by 224% in least developed regions 
(from 490 million to 1·59 billion, or from 8·6% to 20·2% 
of the total population). The accom panying 
epidemiological transition will greatly increase the 
burden of chronic non-communicable diseases, espe-
cially in the most rapidly developing regions.3 
According to the Global Burden of Disease report,2 the 
ﬁ ve leading contributors to YLD in elderly people in 
low-income and middle-income countries are eye 
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diseases, hearing loss, dementia, musculoskeletal 
diseases, and heart disease. Contributions of health 
problems to YLD are determined by their incidence, 
duration, and a disorder-speciﬁ c disability weight. 
Disability weights were established by an international 
panel of health professionals using an iterative person 
trade-oﬀ  approach, and represent implicit societal 
preferences for particular health states. This approach 
has two main limitations. First, other than in the Global 
Burden of Disease report,2 inference of disability from 
diagnoses is not usual practice; it conﬂ icts with the 
contextually interactive notion of disability that is 
outlined by the International Classiﬁ cation of 
Functioning, Disability and Health.1 
Second, many elderly people often have several 
disease comorbidities; the Global Burden of Disease 
investigators aspire to divide disability into components 
that are independently attributable to diﬀ erent health 
problems, but the straightforward additive approach 
that is used is, by Murray and Lopez’s4 admission, 
oversimplistic and ﬂ awed. They provide two main 
justiﬁ cations for this approach.4 The ﬁ rst is the low 
availability of population surveys of health and 
functioning—this limitation applies especially to elderly 
people in countries with low and middle incomes, since 
most comprehensive studies have focused on young 
and middle-aged adults.5–7 The second is the absence of 
a straightforward and widely used measure with a 
universal metric that is capable of assessing disability 
across regions, cultures, and disorders. 
A new instrument, the WHO disability assessment 
schedule (WHODAS) 2.0,8 was developed in parallel 
with the International Classiﬁ cation of Functioning, 
Disability and Health.1 Equal attention was given to its 
conceptual basis (consistent with the International 
Classiﬁ cation) and to its psychometric robustness. A 
key aim was to identify the consequences of any type of 
health problem, treating all disorders at parity in 
assessing levels of function.9 Psychometric testing has 
been rigorous. An early draft (89 items) was tested in 
ﬁ eld trials in 21 sites and 19 countries to ensure cross-
cultural applicability. On the basis of psychometric 
analyses and further ﬁ eld testing, the measure was 
shortened to 36 items, and a 12-item screening 
questionnaire was developed.10 
In the 10/66 Dementia Research Group’s population-
based surveys in India, China, and ﬁ ve countries in 
Latin America, WHODAS 2.0 was administered to 
nearly 15 000 elderly people. Initial analyses of these 
data have established that WHODAS 2.0 is a 
unidimensional scale, conforming to principles of the 
item response theory, and meeting formal criteria for 
measurement invariance across the many countries, 
languages, and cultures represented.11 Participants were 
also assessed comprehensively for chronic-disease 
diagnoses and impairments. We have used these data to 
assess ﬁ rst, the independent contribution of physical, 
mental, and cognitive chronic diseases to disability 
scores across the 10/66 population-based studies, 
comparing our ﬁ ndings with those of the Global Burden 
of Disease report,2 and second, the extent to which 
compositional factors (sociodemographic variables and 
health states) might account for geographical variation 
in disability scores. 
Methods
Participants
One-phase population-based surveys were undertaken, 
between 2003 and 2005, of all elderly people (aged 
65 years and older) living in geographically deﬁ ned 
catchment areas from seven developing countries (urban 
sites in Cuba, Dominican Republic, and Venezuela, and 
urban and rural sites in Mexico, Peru, China, and India). 
The protocol for the baseline survey12 consists of a wide-
ranging participant interview, a structured clinical 
interview, an informant interview, and a physical 
examination. Information is obtained about socio-
demographic characteristics, health status, disability, risk 
factors, anthropometry, health-service use, care 
arrangements, and carer strain. We describe in detail 
only the assessments that are relevant to the present 
analyses. The sample size for each country was between 
2000 and 3000. All studies were approved by local ethical 
committees and by the King’s College London research 
ethics committee.
Procedures
Disability was measured with the 12-item WHODAS 2.0. 
This short version of the WHODAS 2.0 covers all six 
domains of the full 36-item version. Correlation with the 
36-item version of WHODAS 2.0 was 0·95.10 The schedule 
has ﬁ ve activity-limitation domains: understanding or 
communication, getting around (mobility), self-care, 
getting along with people (interpersonal interaction), and 
life activities. A sixth domain, participation in society, 
assesses broad social aspects of disability. Each domain is 
covered by two questions, with scores ranging from 0 (no 
diﬃ  culty) to 4 (extreme diﬃ  culty or cannot do). The 
standardised global score ranges from 0 (non-disabled) 
to 100 (maximum disability). WHODAS 2.0 has high 
internal consistency, moderate to good test–retest 
reliability, and good concurrent validity in many clinical 
populations with chronic disease.9,13–20 
We assessed the psychometric properties of the 12-item 
interviewer-administered WHODAS 2.0 in the 10/66 
Dementia Research Group population-based survey 
samples.11 Strong internal consistency and high factor 
loadings for the one-factor solution showed uni dimen-
sional ity. Furthermore, WHODAS 2.0 conformed to a 
strong Mokken scale in all sites. Measurement invariance 
was substantiated by comparison of conﬁ rmatory factor 
analysis models in which factor loadings were constrained 
or freely estimated across sites, and by the high between-
site correlations in item diﬃ  culties. 
For more on the WHO disability 
assessment schedule see http://
www.who.int/icidh/whodas
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Information about age, sex, marital status, educational 
attainment (deﬁ ned as: none; some, not completed 
primary; completed primary; and completed secondary or 
tertiary) and living circumstances were assessed with a 
standard sociodemographic questionnaire. The ascertain-
ment of previous episodes of stroke or ischaemic heart 
disease was based on self-report (“have you ever been told 
by a doctor that you had a stroke/angina/heart attack?”). 
Stroke was coded only if there was a clear history of 
sudden onset of unilateral paralysis, loss of speech, or 
blindness lasting for more than 24 h, hence excluding 
previous episodes of transient ischaemic attack. Dementia 
was ascertained according to the cross-culturally validated 
10/66 dementia diagnosis algorithm21 and the Diagnostic 
and Statistical Manual of Mental Disorders IV dementia 
criterion22,23 after extensive multidomain cognitive testing 
and clinical and informant interview. A full account is 
provided in our report describing prevalence of dementia 
in baseline survey samples.24 
Depression according to 10th International Classiﬁ  cation 
of Diseases criteria was ascertained with the structured 
geriatric mental state clinical interview.25 Hypertension 
was determined according to European Society of Hyper-
tension criteria (systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥95 mm Hg) or a positive answer 
to the question “have you ever been told by a doctor that 
you have hypertension?”. Chronic obstructive pulmonary 
disease (COPD) was diagnosed in people who responded 
“yes” to the question “do you usually cough up phlegm 
from your chest ﬁ rst thing in the morning?” and whose 
answer to the question “for how many months of the year 
does this usually happen?” was 3 months or more. Diabetes 
was ascertained by a positive answer to the question “have 
you ever been told you had diabetes?”.
Physical impairments were assessed on the basis of 
self-reported paralysis, weakness, or loss of a limb; 
eyesight problems; stomach or intestine problems; 
arthritis or rheumatism; heart problems; hearing 
diﬃ  culties or deafness; breathlessness; diﬃ  culty in 
breathing or asthma; fainting or blackouts; skin disorders, 
such as pressure sores, leg ulcers, or severe burns; or 
persistent cough. Impairments were rated as present if 
they interfered with activities “a little” or “a lot”, as 
opposed to “not at all”.26
Statistical analysis
We used Stata 10.0 for all statistical analyses, using the 
10/66 Dementia Research Group data release 2.0, with 
robust standard errors, adjusted for household clustering. 
For all sites, we describe the sociodemographic 
characteristics of the sample, the prevalence of chronic-
disease diagnoses and impairments, mean WHODAS 2.0 
global disability scores and standard deviations, the 
proportion with WHODAS 2.0 scores of zero, and the 
mean of non-zero scores.
We then modelled eﬀ ect of site on WHODAS 2.0 
scores using zero-inﬂ ated negative binomial regression 
(ZINB). This approach deals with overdispersion and 
zero-inﬂ ation, allowing for excess zeros in count models 
under the assumption that the population is 
characterised by two groups, one in which members 
always have zero counts, and one in which members 
have zero or positive counts. The likelihood of being a 
certain zero is estimated with a logit speciﬁ cation, and 
counts in the second group are estimated with a negative 
binomial speciﬁ cation. The ﬁ rst model included the 
eﬀ ect of site only, ﬁ tting dummy variables for site for 
the zero inﬂ ation and negative binomial count parts of 
the model. The second model also included eﬀ ects of 
age, sex, educational attainment, marital status, and all 
chronic-disease diagnoses and impairments. The aim 
was to compare the eﬀ ect of site before and after 
adjustment for these compositional variables. We also 
checked the appropriateness of the ZINB model 
compared with negative binomial, using the Vuong test 
(which has a standard normal distribution in which 
large positive values favour the ZINB model and large 
negative values favour the negative binomial model), 
and a likelihood-ratio test comparing the ZINB model 
with zero-inﬂ ated Poisson. 
Next, we generated ZINB models, separately for each 
site, to estimate the independent associations of health 
dis orders with disability, controlling for age, sex, educa-
tion, and marital status. After ﬁ tting the ZINB model 
separately by site we used a ﬁ xed-eﬀ ects meta-analysis to 
combine them, estimating degree of heterogeneity using 
Higgins’ I² with approximate 95% CIs.27 We then ﬁ tted 
the same models using a Poisson regression working 
model with the 90th centile of the WHODAS 2.0 
distribution in each site as a threshold; although 
somewhat arbitrary, this approach has been 
recommended for modelling of WHODAS 2.0 scores as 
a dichotomised outcome.28 The aim was to calculate a 
population-attributable prevalence fraction (PAPF) for 
the association between each disorder and high disability 
scores and a total PAPF for their combined eﬀ ect, with 
the Stata aﬂ ogit command. Stata aﬂ ogit estimates the 
individual and combined attributable fractions robustly 
from within the Poisson regression framework. PAPFs, 
when calculated from prevalence ratios in cross-sectional 
studies, represent the proportion of prevalent severe 
disability that could theoretically be avoided if the 
exposure could be removed from the population, with 
eﬀ ect of exposure on both incidence and duration of the 
severe disability state taken into account and the 
assumption of causal relations estimated free of 
confounding. 
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study, and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
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Results
15 022 interviews were completed in 11 sites in seven 
countries. Response proportions varied between 72% 
and 98%, and were 80% or higher in all but two sites 
(urban China and urban India).24 WHODAS 2.0 disability 
assessments were completed for 14 869 participants 
(99%). The webappendix shows distribution of 
sociodemographic characteristics by site. Mean age of 
the participants varied between 71·3 and 75·2 years, and 
was higher in Latin America and urban China than in 
rural China and India. Women accounted for between 
53% and 66% of participants by site. Educational 
attainment was highest in Cuba and urban Peru (only 
3% having no education) and Venezuela (8%). In the 
Dominican Republic, rural Peru, and Mexico, 15–33% 
did not have any education, and in rural China (58%) 
and rural (66%) and urban India (43%) having no 
education was the mode. Pension coverage was 
especially low in the Dominican Republic, rural Peru, 
rural Mexico, rural China, and India; food insecurity 
was prevalent in these sites.
Table 1 shows the prevalence of diagnoses and self-
reported impairments by site. The most common self-
reported impairments were eyesight problems (median 
See Online for webappendix
Cuba 
(n=2937)
Dominican 
Republic 
(n=2001)
Urban Peru 
(n=1380)
Rural Peru 
(n=552)
Venezuela 
(n=1947)
Urban 
Mexico 
(n=1002)
Rural 
Mexico 
(n=1000)
Urban China 
(n=1160)
Rural China 
(n=1002)
Urban India 
(n=1001)
Rural India 
(n=999)
Health disorders
Hypertension 72·9% 
(71·3–74·6)
75·4% 
(73·4–77·3)
52·3% 
(49·6–54·9)
41·3% 
(37·2–45·5)
72·1% 
(70·0–74·0)
67·1% 
(64·2–69·9)
54·4% 
(51·3–57·6)
62·6% 
(59·8–65·3)
49·9% 
(46·5–53·3)
59·5% 
(56·4–62·6)
28·5% 
(25·7–31·4)
Eyesight problems 29·3% 
(27·6–31·0)
39·6% 
(37·4–41·8)
32·9% 
(30·4–35·5)
35·6% 
(31·4–39·7)
39·6% 
(37·3–41·9)
28·4% 
(25·5–31·3)
35·7% 
(32·6–38·8)
16·7% 
(14·5–18·9)
6·5% 
(4·8–8·1)
8·8% 
(7·1–10·6)
22·1% 
(19·6–24·6)
Arthritis or 
rheumatism
21·5% 
(19·9–23·1)
36·7% 
(34·6–38·8)
15·3% 
(13·4–17·3)
6·7% 
(4·6–8·8)
24·3% 
(22·3–26·4)
14·5% 
(12·3–16·8)
22·3% 
(19·7–24·9)
14·2% 
(12·2–16·3)
1·9% 
(1·1–2·8)
18·2% 
(15·7–20·5)
51·1% 
(47·9–54·2)
Diabetes 15·8% 
(17·1–19·9)
14·0% 
(12·4–15·5)
8·7% 
(7·2–10·2)
9·8% 
(7·3–12·3)
16·2% 
(14·4–17·7)
24·5% 
(21·9–27·2)
18·9% 
(16·4–21·4)
16·8% 
(14·7–18·9)
1·0% 
(0·3–1·5)
12·1% 
(10·0–14·1)
6·6% 
(5·0–8·2)
Hearing diﬃ  culties 9·9% 
(8·9–11·01)
12·7% 
(11·2–14·2)
21·6% 
(19·4–23·8)
15·8% 
(12·6–18·9)
14·5% 
(12·9–16·1)
19·7% 
(17·2–22·3)
22·9% 
(20·3–25·5)
12·3% 
(10·3–14·2)
8·6% 
(6·8–10·4)
3·1% 
(1·9–4·2)
14·2% 
(12·1–16·4)
Dementia 10·9% 
(9·8–12·1)
12·0% 
(10·6–13·5)
9·4% 
(7·7–11·1)
6·5% 
(4·5–8·6)
7·4% 
(6·2–8·5)
9·3% 
(7·4–11·1)
8·7% 
(6·9–10·5)
7·3% 
(5·7–8·7)
5·6% 
(4·2–7·0)
7·5% 
(5·8–9·2)
10·8% 
(8·8–12·8)
Stroke 7·8% 
(6·8–8·8)
8·7% 
(7·5–9·9)
8·2% 
(6·7–9·6)
3·6% 
(2·1–5·2)
7·1% 
(5·8–8·2)
6·7% 
(5·2–8·2)
7·4% 
(5·7–9·1)
9·4% 
(7·7–11·1)
1·8% 
(0·9–2·6)
1·9% 
(1·1–2·8)
1·1% 
(0·4–1·7)
Stomach or intestine 
problems
8·7% 
(7·7–9·8)
19·3% 
(17·6–21·1)
17·6% 
(15·5–19·7)
5·8% 
(3·8–7·7)
18·8% 
(17·1–20·7)
12·6% 
(10·6–14·7)
17·5% 
(15·2–19·9)
5·7% 
(4·4–7·2)
1·2% 
(0·5–1·8)
2·3% 
(1·4–3·2)
5·0% 
(3·6–6·4)
Heart problems 8·1% 
(7·2–9·1)
4·6% 
(3·7–5·5)
3·9% 
(2·8–4·9)
2·5% 
(1·2–3·8)
9·6% 
(8·3–10·9)
3·9% 
(2·7–5·1)
2·3% 
(1·4–3·2)
28·4% 
(25·7–31·0)
3·1% 
(2·1–4·2)
1·8% 
(0·9–2·6)
0·5% 
(0·1–0·9)
Myocardial infarction 
or angina
14·2% 
(12·8–15·4)
2·9% 
(2·3–3·7)
6·6% 
(5·2–7·9)
4·4% 
(2·7–6·1)
6·2% 
(5·1–7·3)
3·8% 
(2·7–5·1)
1·5% 
(0·7–2·3)
9·9% 
(8·2–11·7)
1·2% 
(0·5–1·8)
4·8% 
(3·5–6·3)
2·8% 
(1·7–3·8)
Diﬃ  culty breathing 
or asthma
7·1% 
(6·1–7·9)
9·5% 
(8·2–10·8)
4·9% 
(3·7–6·1)
4·2% 
(2·5–5·8)
9·1% 
(7·7–10·3)
5·3% 
(3·9–6·6)
5·4% 
(3·9–6·8)
4·5% 
(3·3–5·6)
1·9% 
(1·1–2·7)
5·7% 
(4·3–7·1)
10·7% 
(8·8–12·6)
Depression 4·9% 
(4·1–5·7)
13·8% 
(12·3–15·4)
6·3% 
(4·9–7·6)
2·9% 
(1·5–4·3)
5·4% 
(4·5–6·4)
4·7% 
(3·4–5·9)
4·5% 
(3·2–5·8)
0·3% 
(0·0–0·5)
0·7% 
(0·2–1·2)
3·8% 
(2·7–5·1)
12·6% 
(10·5–14·7)
Paralysis or weakness 
of limb(s)
2·8% 
(2·2–3·4)
5·1% 
(4·2–6·1)
3·2% 
(2·2–4·1)
1·3% 
(0·3–2·2)
9·1% 
(7·7–10·3)
3·4% 
(2·3–4·5)
2·5% 
(1·5–3·5)
6·2% 
(4·8–7·6)
4·4% 
(3·2–5·6)
1·5% 
(0·7–2·3)
2·6% 
(1·6–3·6)
Persistent cough 1·7% 
(1·2–2·2)
10·3% 
(8·9–11·6)
4·5% 
(3·4–5·6)
2·4% 
(1·1–3·6)
8·8% 
(7·5–10·2)
5·8% 
(4·4–7·2)
4·4% 
(3·2–5·6)
2·8% 
(1·9–3·8)
13·9% 
(0·6–2·2)
2·8% 
(1·8–3·9)
6·7% 
(5·2–8·3)
COPD 3·9% 
(3·2–4·6)
6·8% 
(5·7–7·9)
5·9% 
(4·6–7·2)
1·9% 
(0·8–3·2)
6·7% 
(5·6–7·9)
5·8% 
(4·4–7·3)
8·0% 
(6·3–9·6)
3·1% 
(2·1–4·1)
1·6% 
(0·8–2·4)
1·8% 
(0·9–2·6)
7·6% 
(5·9–9·3)
Skin disorders 1·2% 
(0·7–1·5)
1·9% 
(1·4–2·5)
7·2% 
(5·8–8·6)
1·5% 
(0·5–2·5)
3·9% 
(3·1–4·8)
3·4% 
(2·3–4·5)
3·6% 
(2·5–4·7)
1·1% 
(0·5–1·6)
0·2% 
(0·0–0·5)
0·9% 
(0·3–1·5)
3·2% 
(2·1–4·3)
Fainting or blackouts 1·1% 
(0·6–1·4)
3·5% 
(2·7–4·4)
1·7% 
(0·9–2·4)
0·9% 
(0·1–1·7)
3·9% 
(3·1–4·7)
0·5% 
(0·1–0·9)
1·8% 
(0·9–2·6)
5·4% 
(4·1–6·7)
0·9% 
(0·4–1·6)
1·5% 
(0·7–2·3)
10·5% 
(8·6–12·4)
WHODAS 2.0
Mean scores (SD) 13·4 
(20·0)
16·5 
(20·3)
13·0 
(20·6)
10·4 
(14·5)
10·7 
(16·4)
10·0 
(17·3)
11·1 
(19·1)
8·1 
(20·1)
8·0 
(14·5)
10·5 
(15·4)
28·3 
(18·3)
Zero scores (%) 37·8% 31·4% 40·4% 33·6% 41·4% 48·3% 51·3% 75·7% 56·4% 47·7% 2·3%
Mean scores (SD) 
omitting zeros
21·5 
(21·7)
24·0 
(20·5)
21·9 
(22·7)
15·7 
(15·4)
18·3 
(17·8)
19·3 
(19·9)
22·7 
(22·0)
33·2 
(28·9)
18·7 
(17·2)
16·9 
(16·6)
28·9 
(17·9)
Data are percentage (95% CI), unless otherwise stated. COPD=chronic obstructive pulmonary disease. WHODAS=WHO disability assessment schedule. 
Table 1: Prevalence of health disorders and mean WHODAS 2.0 scores by site
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prevalence 28·4% [IQR 6·5–39·6]), arthritis or 
rheumatism (18·2% [1·9–51·1]), hearing diﬃ  culties 
(14·2% [3·1–22·9]), and gastrointestinal problems (8·7% 
[1·2–19·3]). Paralysis or weakness of limbs, heart 
problems, diﬃ  culty in breathing or asthma, fainting or 
blackouts, skin disorders, and persistent cough were 
reported by fewer than 10% of participants, for almost all 
sites. The most common diagnosis was hypertension 
(median prevalence 62·6% [28·5–75·4]), followed by 
diabetes (14·0% [1·0–24·5]), dementia (8·7% [5·6–12·0]), 
stroke (7·1% [1·1–8·7]), COPD (5·8% [1·6–7·6]), 
depression (4·7% [0·3–13·8]), and ischaemic heart 
disease (4·4% [1·2–14·2]). 
Distribution of WHODAS 2.0 scores varied greatly 
between sites. Most of the variation was accounted for by 
two sites: urban China, with a high proportion of zero 
scores (75·7%) and hence a low mean score, and rural 
India, with a very low proportion (2·3%) of zero scores 
and hence a high mean score. The ﬁ rst ZINB model 
(table 2) assessed eﬀ ect of site on WHODAS 2.0 disability 
scores. This model showed that most of the between-site 
variation arose from zero inﬂ ation, which was most 
pronounced in China (particularly urban China) and least 
evident in rural India. The between-site variation that was 
estimated in the negative binomial count part of the 
model was small, and (with the exception of rural India) 
diminished after adjustment for compositional diﬀ erences 
between sites in chronic disease, age, sex, education, and 
marital status. However, between-site variation in zero 
inﬂ ation was not reduced after adjustment for these 
variables. For this ﬁ nal model, ZINB ﬁ tted better than did 
negative binomial (Vuong test, z=76·5, p<0·0001, 
suggesting substantial zero inﬂ ation) or zero-inﬂ ated 
Poisson models (α=0·52 [95% CI 0·50–0·54], χ²=62 000, 
p<0·0001, showing substantial overdispersion).
Table 3 shows independent associations between 
health disorders and WHODAS 2.0 disability score 
counts from the ZINB models, listed in order of eﬀ ect 
size (pooled meta-analysed relative risk [RR]). The largest 
eﬀ ect sizes and most consistently signiﬁ cant associations 
across sites were recorded for dementia, paralysis or 
weakness of a limb, depression, stroke, and arthritis or 
rheumatism. All eﬀ ects in the model were signiﬁ cant 
after pooled meta-analysis other than those for 
myocardial infarction or angina, COPD, and 
hypertension. However, heterogeneity was severe 
(I²>56%) for dementia, paralysis or weakness of a limb, 
depression, skin disorders, eyesight problems, and 
myocardial infarction or angina. Patterns of heterogeneity 
varied between disorders, and closer inspection did not 
reveal any obvious source.  
We calculated PAPFs from a Poisson regression 
working model, using the 90th centile of the WHODAS 
2.0 score in each site as a threshold to identify severe 
disability (table 4). In every site other than rural India 
and Venezuela, dementia made the largest contribution 
to severe disability. Other substantial contributors were 
stroke, paralysis or weakness of limbs, arthritis or 
rheumatism, depression, eyesight problems, and 
stomach or intestine problems. Although the PAPF for 
hypertension was substantial in several sites, none of the 
underlying associations were signiﬁ cant. In rural Peru, 
which was the site with the smallest sample, chronic-
disease impairments and diagnoses were collectively 
associated with a PAPF of 40·1%. Across all other sites, 
total PAPF ranged from 61·8% to 74·5%. 
Discussion
WHO’s Global Burden of Disease report provides 
important evidence for the relative eﬀ ects of health 
disorders worldwide,2,29 aﬀ ecting prioritisation for policy 
making and planning nationally, regionally, and 
internationally. However, the rank ordering of the 
contributions of chronic diseases to disability that were 
noted in this report diﬀ er in important respects from 
those estimated from results of the 10/66 population-
based surveys (table 5). In our studies, dementia is 
overwhelmingly and consistently the largest contributor 
to disability. Sensory impairment, both of eyesight and 
Crude model Adjusted model*
Zero inﬂ ation
Cuba 1† ··
Dominican Republic 0·75 (0·66–0·86) 1·08 (0 ·93–1·26)
Peru (urban) 1·12 (0·97–1·30) 1·10 (0·93–1·28)
Peru (rural) 0·79 (0·64–0·99) 0·57 (0·45–0·73)
Venezuela 1·16 (1·02–1·32) 1·24 (1·07–1·44)
Mexico (urban) 1·55 (1·33–1·81) 1·67 (1·39–2·00)
Mexico (rural) 1·78 (1·53–2·07) 2·16 (1·79–2·60)
China (urban) 5·42 (4·57–6·36) 6·89 (5·70–8·33)
China (rural) 2·26 (1·93–2·65) 1·37 (1·13–1·66)
India (urban) 0·97 (0·83–1·14) 0·64 (0·53–0·77)
India (rural) 0·01 (0·00–0·11) 0·02 (0·01–0·05)
Count
Cuba 1† ··
Dominican Republic 1·12 (1·05–1·20) 1·01 (0·95–1·07)
Peru (urban) 1·02 (0·93–1·11) 1·03 (0·96–1·11)
Peru (rural) 0·72 (0·64–0·81) 0·96 (0·87–1·06)
Venezuela 0·84 (0·78–0·91) 0·86 (0·80–0·91)
Mexico (urban) 0·89 (0·80–0·99) 0·97 (0·88–1·07)
Mexico (rural) 1·06 (0·96–1·17) 1·14 (1·03–1·25)
China (urban) 1·56 (1·39–1·76) 1·27 (1·14–1·41)
China (rural) 0·87 (0·78–0·96) 1·14 (1·05–1·23)
India (urban) 0·78 (0·71–0·86) 1·09 (1·00–1·19)
India (rural) 1·36 (1·27–1·44) 1·65 (1·55–1·77)
Data for zero inﬂ ation are odds ratio (95% CI); data for count are ratio of counts 
(95% CI). WHODAS=WHO disability assessment schedule. *Adjusted for age, sex, 
educational attainment, marital status, and all chronic-disease diagnoses and 
impairments. †Reference.
Table 2: Between-site variation in zero inﬂ ation and WHODAS 2.0 score 
counts as modelled by zero-inﬂ ated negative binomial regression, 
before and after adjustment for compositional factors
Articles
1826 www.thelancet.com   Vol 374   November 28, 2009
hearing, and heart disease contributed much less to 
disability than was suggested by the Global Burden of 
Disease estimates. According to our ﬁ ndings, stroke and 
arthritis merit a high ranking, especially since some of 
the eﬀ ect of limb paralysis or weakness (with a median 
PAPF of 10·5%) almost certainly arises from these two 
diagnoses, which could well have been under-reported 
in our surveys.
Zero-inﬂ ated negative binomial regression was the 
most appropriate statistical method for modelling of 
Cuba DR Urban 
Peru
Rural Peru Venezuela Urban 
Mexico
Rural 
Mexico
Urban 
China
Rural 
China
Urban 
India
Rural 
India
Meta-
analysed 
RR (95% CI)
Q 
value 
I² value 
(95% CI)
Dementia 2·44 
(2·19–
2·71) 
1·57 
(1·38–
1·78) 
2·66 
(2·25–
3·15)
2·03 
(1·52–
2·71) 
1·99 
(1·67–
2·39) 
1·72 
(1·27–
2·31) 
2·03 
(1·61–
2·56) 
2·15 
(1·78–
2·60) 
1·86 
(1·55–
2·24) 
1·85 
(1·52–
2·27) 
1·32 
(1·18–
1·47) 
1·88 
(1·79–1·98)
93·6 89% 
(83–93)
Paralysis or 
weakness of 
limb(s)
1·96 
(1·67–
2·29) 
1·91 
(1·68–
2·15) 
1·48 
(1·07–
2·05) 
1·46 
(0·94–
2·27)* 
1·38 
(1·21–
1·59) 
1·31 
(0·97–
1·75)* 
1·86 
(1·24–
2·78) 
2·34 
(1·76–
3·11) 
2·11 
(1·69–
2·64) 
2·62 
(1·88–
3·64)
1·53 
(1·21–
1·94) 
1·76 
(1·65–1·87)
34·1 71% 
(46–84)
Depression 1·62 
(1·42–
1·84) 
1·42 
(1·29–
1·56) 
1·45 
(1·19–
1·75)
1·86 
(1·21–
2·86) 
1·58 
(1·33–
1·89) 
1·39 
(1·09–
1·77) 
1·51 
(1·21–
1·88) 
0·98 
(0·41–
2·36)* 
2·08 
(1·57–
2·76) 
1·56 
(1·21–
2·02) 
1·02 
(0·92–
1·14)* 
1·39 
(1·32–1·46)
50·7 80% 
(66–89)
Stroke 1·38 
(1·23–
1·55) 
1·34 
(1·18–
1·53) 
1·76 
(1·37–
2·25) 
1·56 
(1·03–
2·37) 
1·42 
(1·21–
1·66) 
1·88 
(1·40–
2·53) 
1·19 
(0·89–
1·59) 
1·05 
(0·78–
1·39)* 
1·19 
(0·88–
1·61)* 
1·57 
(1·10–
2·24) 
1·46 
(0·96–
2·21)* 
1·39 
(1·31–1·48)
14·6 32% 
(0–66)
Arthritis or 
rheumatism
1·41 
(1·30–
1·53) 
1·32 
(1·21–
1·44) 
1·35 
(1·17–
1·55) 
1·32 
(0·98–
1·75)* 
1·29 
(1·15–
1·45) 
1·51 
(1·22–
1·87) 
1·45 
(1·23–
1·71) 
1·06 
(0·85–
1·33)*
1·24 
(0·73–
2·11)* 
1·37 
(1·19–
1·57) 
1·28 
(1·20–
1·37) 
1·33 
(1·28–1·38)
9·7 0% 
(0–60)
Fainting or 
blackouts 
1·21 
(0·91–
1·61)* 
1·23 
(1·03–
1·48) 
1·17 
(0·84–
1·66)* 
1·02 
(0·57–
1·79)* 
1·04 
(0·85–
1·27)* 
1·44 
(0·73–
2·82)* 
0·97 
(0·69–
1·37)* 
0·96 
(0·69–
1·33)* 
1·31 
(0·93–
1·85)* 
1·14 
(0·82–
1·58)* 
1·37 
(1·26–
1·49) 
1·25 
(1·17–1·34)
13·2 24% 
(0–62)
Diﬃ  culty 
breathing or 
asthma
1·28 
(1·13–
1·45)
1·13 
(1·01–
1·28) 
1·26 
(1·01–
1·58) 
1·35 
(0·92–
1·98)* 
1·13 
(0·95–
1·33)* 
1·11 
(0·84–
1·45)*
1·17 
(0·89–
1·54)* 
1·14 
(0·84–
1·56)* 
1·26 
(0·79–
2·03)* 
1·18 
(0·84–
1·48)* 
1·21 
(1·08–
1·33) 
1·19 
(1·13–1·26)
4·4 0% 
(0–60)
Skin disorders 1·39 
(1·12–
1·74) 
1·73 
(1·39–
2·13) 
1·17 
(0·98–
1·41) 
1·86 
(1·32–
2·63) 
1·04 
(0·84–
1·28)* 
0·99 
(0·61–
1·63)* 
0·86 
(0·64–
1·16)*
0·97 
(0·65–
1·45)* 
0·99 
(0·59–
1·68)* 
1·35 
(0·53–
3·47)* 
1·02 
(0·87–
1·19)* 
1·18 
(1·10–1·28)
32·2* 69% 
(42–83)*
Stomach or 
intestine 
problems
1·15 
(1·03–
1·29)
1·26 
(1·15–
1·38) 
0·96 
(0·84–
1·11)* 
1·37 
(0·91–
2·06)* 
1·07 
(0·96–
1·21)* 
0·98 
(0·79–
1·22)* 
1·23 
(1·03–
1·46) 
1·05 
(0·76–
1·44)* 
1·03 
(0·71–
1·51)* 
1·06 
(0·75–
1·48)* 
1·17 
(1·04–
1·33) 
1·14 
(1·09–1·19)
16·1* 38% 
(0–69)*
Diabetes 1·07 
(0·97–
1·16)*
1·05 
(0·95–
1·16)*
1·22 
(1·01–
1·46)
1·47 
(1·05–
2·06)
1·18 
(1·05–
1·33)
1·11 
(0·93–
1·32)*
1·23 
(1·02–
1·49)
1·13 
(0·89–
1·43)*
0·85 
(0·44–
1·62)*
1·16 
(0·96–
1·42)*
1·08 
(0·95–
1·22)*
1·12 
(1·06–1·16)
9·1 0% 
(0–60)
Eyesight 
problems
1·22 
(1·12–
1·32)
1·13 
(1·04–
1·23)
0·91 
(0·79–
1·03)*
1·15 
(0·96–
1·36)* 
1·01 
(0·89–
1·13)* 
1·04 
(0·86–
1·24)* 
0·99 
(0·85–
1·16)* 
1·02 
(0·81–
1·28)* 
1·01 
(0·79–
1·28)* 
1·72 
(1·36–
2·15) 
1·11 
(1·03–
1·18) 
1·11 
(1·06–1·14)
34·7 71% 
(47–84)
Hearing 
diﬃ  culties 
1·09 
(0·98–
1·22)* 
1·18 
(1·06–
1·32) 
1·17 
(1·03–
1·34) 
1·07 
(0·85–
1·35)* 
1·15 
(1·01–
1·33) 
1·24 
(1·04–
1·49) 
1·02 
(0·85–
1·22)* 
0·92 
(0·74–
1·14)* 
0·99 
(0·79–
1·25)* 
1·22 
(0·81–
1·82)* 
1·04 
(0·95–
1·15)* 
1·11 
(1·06–1·15)
10·6 6% 
(0–63)
Persistent 
cough 
1·37 
(1·12–
1·68) 
1·01 
(0·89–
1·13)* 
1·14 
(0·89–
1·45)*
1·02 
(0·69–
1·51)* 
1·12 
(0·94–
1·32)* 
1·09 
(0·81–
1·51)* 
0·88 
(0·66–
1·18)* 
0·89 
(0·58–
1·38)* 
1·38 
(0·78–
2·45)* 
1·41 
(0·98–
2·02)* 
1·13 
(1·00–
1·28) 
1·11 
(1·04–1·17)
12·9 23% 
(0–61)
Heart 
problems 
1·07 
(0·95–
1·21)* 
1·12 
(0·96–
1·29)* 
1·01 
(0·83–
1·24)* 
1·19 
(0·79–
1·81)* 
1·04 
(0·88–
1·23)* 
1·03 
(0·61–
1·73)* 
0·93 
(0·57–
1·51)* 
1·42 
(1·11–
1·83) 
1·07 
(0·73–
1·58)* 
1·35 
(0·77–
2·35)* 
1·17 
(0·84–
1·63)* 
1·09 
(1·02–1·17)
6·6 0% 
(0–60)
Myocardial 
infarction or 
angina
1·06 
(0·95–
1·19)* 
1·03 
(0·84–
1·26)* 
1·19 
(0·97–
1·45) 
0·86 
(0·58–
1·27)* 
1·34 
(1·14–
1·58) 
0·82 
(0·53–
1·25)* 
0·37 
(0·22–
0·64) 
0·82 
(0·60–
1·12)* 
0·99 
(0·54–
1·82)* 
1·02 
(0·73–
1·42)* 
0·91 
(0·73–
1·12)* 
1·05 
(0·98–1·12)*
30·7* 67% 
(39–83)*
COPD 1·03 
(0·86–
1·24)*
1·04 
(0·91–
1·18)* 
0·83 
(0·65–
1·06)* 
0·58 
(0·39–
0·87) 
1·15 
(0·97–
1·36)* 
1·09 
(0·81–
1·47)* 
1·11 
(0·88–
1·38)* 
1·14 
(0·79–
1·66)* 
1·31 
(0·87–
1·94)* 
1·12 
(0·78–
1·57)* 
0·96 
(0·85–
1·09)* 
1·02 
(0·96–1·08)*
16·2* 38% 
(0–70)*
Hypertension 0·99 
(0·91–
1·08)* 
0·98 
(0·89–
1·10)* 
1·09 
(0·97–
1·24)* 
0·94 
(0·78–
1·12)* 
1·05 
(0·92–
1·21)* 
1·16 
(0·98–
1·37)* 
1·13 
(0·96–
1·34)* 
1·00 
(0·82–
1·22)* 
0·91 
(0·79–
1·03)* 
1·09 
(0·96–
1·25)* 
0·98 
(0·91–
1·05)* 
1·02 
(0·97–1·05)*
12·4* 20% 
(0–59)*
Data are relative risk (RR; 95% CI), unless otherwise stated. DR=Dominican Republic. COPD=chronic obstructive pulmonary disease. *Associations were not signiﬁ cant. †Adjusted for age, sex, educational 
attainment, and marital status. 
Table 3: Relative risks for associations between disability and self-reported impairments and chronic-disease diagnoses† 
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WHODAS 2.0 disability scores, especially in a cross-
cultural context. Score distributions were overdispersed 
and zero-inﬂ ated in all sites, and ZINB models ﬁ tted 
better than did either Poisson or negative binomial. The 
large between-site variation in zero inﬂ ation is an 
important ﬁ nding, with the positive association with 
zero inﬂ ation in China and inverse association in India 
being most parsimoniously interpreted as a culturally 
determined predisposition to so-called nay-saying in 
China and yea-saying in the Indian setting. Having 
accounted for zero inﬂ ation, the count (negative 
binomial) part of the ZINB model provides the best, 
most culturally fair perspective on the contribution of 
chronic diseases to overall disability (table 3). 
Unfortunately, since this method models the ratio of 
counts, we were unable to use these values to generate 
estimates of population eﬀ ect (either PAPFs or 
components of variance explained). That our PAPFs had 
to be generated from a Poisson model (table 4) is 
therefore a slight limitation. 
Our ﬁ ndings are consistent with a report from the 
Canadian Study of Health and Aging30 of a substantial 
excess disability attributable to dementia, after 
accounting, in multivariate models for comorbidity 
with physical, mental, and substance-use disorders. In 
population-based cohort studies of predictors of 
dependency31 and institutionalisation32 in elderly people 
in the USA, multivariable analyses show that dementia 
and cognitive impairment are by far the most strongly 
and independently associated chronic health disorders. 
Psychiatric disorders and stroke also made an important 
independent contribution to dependency.31 Coronary 
heart disease, cancer, hypertension, lung disease, 
diabetes, and hip fracture did not predict dependency, 
and cardiovascular disease, arthritis, and lung disease 
were not associated with institutionalisation. Few such 
studies have been done in countries with low and 
middle incomes. However, in a cross-sectional study33 
of elderly Chinese people living in Hong Kong, 
dementia (odds ratio 157·1), stroke (19·3), Parkinson’s 
disease (14·2), and old fractures (2·5) were the chronic 
disorders most strongly associated with severe 
limitation. Finally, previous analyses of the same 10/66 
Dementia Research Group dataset have shown that 
dementia is the largest independent chronic disease 
contributor to dependency, with a PAPF of 65% in 
Cuba34 and 44% in Dominican Republic.35 
Some limitations need to be acknowledged. First, we 
did not include all chronic-disease domains in our 
analyses. Presence of cancer or endocrine, genitourinary, 
and oral disorders was not ascertained. However, 
according to the Global Burden of Disease report,2 these 
excluded disorders make a small contribution to 
disability, and those that were covered in our study 
Cuba Dominican 
Republic
Urban 
Peru
Rural 
Peru
Venezuela Urban 
Mexico
Rural 
Mexico
Urban 
China
Rural 
China
Urban 
India
Rural 
India
PAPF (IQR)
Dementia 43·6% 25·1% 43·2% 22·5% 19·2% 22·4% 21·6% 35·1% 38·9% 19·9% 26·1% 25·1% (19·2–43·6)
Hypertension * 14·4%† 2·1%† * 18·3%† 11·8%† 13·8%† * 16·8%† 15·9%† * 14·4% (2·1–18·3)
Stroke 11·4% 7·9% 21·4% 13·8% 12·3% 15·4% 7·5%† 21·1%† 1·8%† 6·2% 5·0%† 11·4% (1·8–21·4)
Paralysis or weakness 
of limb(s)
10·5% 21·3% 7·1% 5·7%† 11·6% 7·5%† 10·4% 30·5% 33·8% 7·9% 11·3% 10·5% (5·7–33·8)
Arthritis or 
rheumatism
9·9% 14·1% 8·9% 3·2%† 21·1% 9·4% 21·6% 3·3%† 5·6%† 14·4% 34·8% 9·9% (3·2–34·8)
Depression 8·3% 23·0% 7·8% 15·4% 10·8% 6·2% 12·4% 0·5%† 1·7% 8·3% 1·2%† 8·3% (0·5–23·0)
Eyesight problems 17·6% 5·1% * * 6·8%† 5·4%† * 1·7%† 10·8%† 12·1% 17·2% 6·8% (1·7–17·6)
Stomach or intestine 
problems
3·3% 14·1% * 10·5%† 4·8%† 6·5%† 23·1% * 0·3%† 2·5%† 7·9% 6·5% (0·3–23·1)
Diabetes 2·5%† * 3·3% 8·3% 5·1% 4·1%† 10·9% 5·0%† 0·3%† 3·2%† * 4·1% (0·3–10·9)
Diﬃ  culty breathing 
or asthma
5·3% 8·9% * 2·2%† * 4·3%† 2·1%† 3·7%† 3·2%† * 8·5% 3·7% (2·1–8·9)
Hearing diﬃ  culties 2·2%† 8·9% 1·4% * 6·1% 9·3% 1·1%† * 3·0%† 0·8%† * 2·2% (0·8–9·3)
COPD <0·1%† 2·5%† * * 5·1%† 1·7%† 7·2%† 7·4%† 3·3%† * * 3·3% (<0·1–7·4)
Persistent cough 1·4% * 1·3%† * 5·4%† 2·2%† * * 2·3%† 5·0%† 5·3% 2·3% (1·3–5·4)
Fainting or blackouts 0·8%† 1·2% 2·1%† * * 0·5%† * 1·2%† 2·2%† * 17·1% 1·2% (0·5–17·1)
Heart problems * 1·6%† 4·4%† * 1·8%† * 0·3%† 15·9% 0·9%† 3·2%† 0·5%† 1·6% (0·5–15·9)
Skin disorders 1·3% 4·4% 4·5%† 3·1% * 2·1%† * * * <0·1%† 0·2%† 2·1% (<0·1–4·5)
Myocardial 
infarction or angina
3·1%† * * 0·8%† 4·7% * * * * * 0·8%† 0·8% (0·8–4·7)
Total 68·3% 74·5% 62·7% 40·1% 68·3% 64·3% 68·3% 65·1% 69·2% 61·8% 67·6% 67·6% (40·1–74·5)
PAPF=population-attributable prevalence fraction. COPD=chronic obstructive pulmonary disease. WHODAS=WHO disability assessment schedule. *Inverse associations, which were assigned a PAPF value of zero 
for the purpose of calculation of median population-attributable prevalence fractions. †Calculated from associations that were not signiﬁ cant. 
Table 4: Population-attributable prevalence fractions for 90th centile of WHODAS 2.0 scores and health disorders
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generally accounted for a substantial proportion of 
disability. Second, and more importantly, not all 
disorders that were included were ascertained with 
equivalent rigour. Amartya Sen emphasised the problem 
of self-report, pointing out that “people in states that 
provide more education and better health facilities are 
in a better position to diagnose and perceive their own 
morbidities than are the people in less advantaged 
states, where there is less awareness of treatable 
conditions (to be distinguished from ‘natural’ states of 
being)”.36 Our data did not provide very strong evidence 
for this problem, other than, perhaps, with respect to 
the low prevalence of self-reported stroke in rural China 
and India, myocardial infarction or angina in rural 
Mexico, China, and India, and diabetes in rural India 
and rural China. 
Prevalences of all self-reported impairments were 
strikingly low in rural compared with urban China, and 
eyesight problems were infrequently reported in urban 
India. We cannot exclude the possibility that had we 
diagnosed some of these disorders by more rigorous 
clinical assessment, we might have identiﬁ ed more 
morbidity. By extension, we might have underestimated 
their contribution to disability in the population with 
respect to that of dementia and depression, which were 
diagnosed through detailed clinical interviews. However, 
despite the fairly low prevalence of eyesight problems in 
rural China and in India, high PAPFs were recorded, 
presumably because of poor access to ophthalmic 
services, and because we selectively detected the most 
disabling cases. 
Third, our data are cross-sectional. Therefore we 
cannot attribute causality from the recorded associations 
between health disorders and disability. Some 
associations might have been inﬂ ated by reverse 
causality, thus depression can be both a consequence 
and a cause of disability.37 Information bias could have 
occurred, since participants with disabilities might have 
been selectively more or less likely to have recalled 
impairments or to have been aware of diagnoses than 
were those without disabilities. Although population-
attributable fractions are conventionally calculated from 
RRs for incident health outcomes, associations with 
prevalent disability might be more pertinent to our 
aims. Our PAPFs incorporate the eﬀ ect of underlying 
health disorders on the incidence and duration of 
disability, and are hence analogous with the YLD 
approach that was used for the Global Burden of Disease 
report.2 
The need to internationalise the disability research 
agenda is the subject of an important debate. Limitations 
arise from diﬀ erences in disability deﬁ nitions, study 
methods, and qualities of research across cultural 
contexts. The major strength of our study is the standard 
design and assessment procedures, in large representative 
samples, with high response rates, across three 
continents. From the outset, the 10/66 Dementia 
Research Group has been committed to careful cross-
cultural validation,21 and we have now attempted to 
extend this approach to assessment of disability,11 in 
accordance with the evidence already assembled by WHO 
for the cross-cultural applicability of the International 
Classiﬁ cation of Functioning, Disability and Health1 and 
the WHODAS 2.0 assessment. Although the approach 
we have used to estimate the contribution of chronic 
diseases to disability could not replace that used for the 
Global Burden of Disease report,2 comparison of the 
results of these two exercises is illuminating. Such 
comparison does, at the least, raise important questions 
about the reasons for the large discrepancies, which 
would merit further exploration. One possibility is that 
societal preferences (the Global Burden of Disease 
disability weights) might not accurately show individual 
experiences of living with chronic disease (as assessed by 
the WHODAS 2.0). 
Our ﬁ ndings should help to inform debates about 
priorities for health-service delivery and planning in 
countries with low and middle incomes. Our ﬁ ndings 
concur with those of the Global Burden of Disease 
report,2 to the extent that the leading causes of disability 
are very diﬀ erent from the causes of premature death, 
namely cancer and ischaemic heart disease. The 
chronic-disease agenda is dominated by prevention of 
avoidable deaths, and is hence skewed towards primary 
prevention of these disorders.38 Of course, prevention 
of chronic diseases also prevents disability. However, 
YLD (×10⁶) (contribution to 
total chronic-disease YLDs [%])
Rank order 
(by YLD)
PAPF* Rank order 
(by PAPF)
Dementia 8·3 (10·2%) 3 25·1% 1
Cerebrovascular diseases 3·5 (4·3%) 8 11·4% 2
Musculoskeletal diseases 7·2 (8·9%) 4 9·9%† 3
Neuropsychiatric diseases 
(other than dementia)
5·9 (7·3%) 6 8·3% 4
Eye diseases 27·5 (33·9%) 1 6·8% 5
Digestive diseases 1·6 (1·9%) 11 6·5% 6
Diabetes mellitus 2·1 (2·6%) 10 4·1% 7
Respiratory conditions 4·3 (5·3%) 7 3·3%‡ 8
Hearing loss 9·2 (11·3%) 2 2·2% 9
Skin conditions 0·5 (0·6%) 15 2·1% 10
Heart disease 6·1 (7·6%) 5 0·8%§ 11
Oral conditions 2·6 (3·3%) 9 Not assessed ··
Malignant neoplasm 0·9 (1·1%) 12 Not assessed ··
Endocrine disorders 0·8 (1·0%) 13 Not assessed ··
Genitourinary diseases 0·6 (0·7%) 14 Not assessed ··
Total chronic disease burden 81·1 (100%) ·· ·· ··
YLD=years lived with disability. PAPF=population-attributable prevalence fraction. *From directly measured 
association with WHO disability assessment schedule 2.0. †Self-reported arthritis or rheumatism. ‡Self-reported 
symptoms of chronic obstructive pulmonary disease. §Self-reported angina or myocardial infarction. ¶For people aged 
60 years and older in countries with low and middle incomes (2004).
Table 5: Contributions of chronic diseases and disorders to disability according to Global Burden of 
Disease estimates of years lived with disability¶ and median population-attributable prevalence 
fractions from 10/66 population-based studies
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under the most optimistic of scenarios, the numbers of 
elderly people living with disabling chronic diseases 
will continue to rise, especially in countries with low 
and middle incomes. Our data suggest the need, in 
particular, for higher priority to be accorded to chronic 
diseases aﬀ ecting the brain and mind. Aside from 
disability, these disorders are very likely to lead to 
dependency, and to present stressful, complex, long-
term challenges to carers. The associated societal costs 
are enormous—those for dementia alone were 
estimated as US$315 billion per year worldwide.39 These 
individuals, and their families, are very poorly served by 
health services that remain focused on treatment of 
acute disorders, and do not provide outreach or 
continuing care; social protection for elderly people in 
many countries with low and middle incomes is also 
grossly inadequate.40 
A comprehensive response to these challenges will 
need policies to: prevent disability through control of 
chronic diseases; reduce disability through active 
community-based rehabilitation; mitigate eﬀ ects of 
disability on participation; and manage disability 
through universal access to support for family carers 
and other long-term care options. Such measures are 
already strongly advocated through international 
agreements, including the Madrid International Plan 
for Action on Ageing, and the UN Convention on the 
Rights of Persons with Disabilities enshrines 
participation, income, and access to health care as basic 
rights for all people with disabilities. 
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